<SEC-DOCUMENT>0001193125-24-199818.txt : 20240813
<SEC-HEADER>0001193125-24-199818.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813163404
ACCESSION NUMBER:		0001193125-24-199818
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281522
		FILM NUMBER:		241202249

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d792594ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August&nbsp;13, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-2142067</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>149 Fifth Street, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">994-8250</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
Registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jennifer S.
Buell, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>President, Chief Executive Officer and Director </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>149 Fifth Street, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">994-8250</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent
for service) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Zachary
Blume </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Ropes&nbsp;&amp; Gray LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Prudential Tower </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>800
Boylston Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02199-3600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">951-7000</FONT> </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of
commencement of proposed sale to the public: From time to time after this registration statement becomes effective. </B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being
registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of the
securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box.&#8194;&#9746; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&#8194;&#9744; </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a) may determine.
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information contained in this prospectus is not complete and may be changed. The
selling stockholder named in this prospectus may not sell these securities until the registration statement becomes effective. This prospectus is not an offer to sell these securities, and the selling stockholder named in this prospectus is not
soliciting offers to buy these securities in any jurisdiction where the offer for sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject To Completion, Dated August&nbsp;13, 2024 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g792594g79d59.jpg" ALT="LOGO" STYLE="width:2.86126in;height:0.914129in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>4,640,000 SHARES OF COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the disposition from time to time of up to 4,640,000 shares of our common stock, $0.00001 par value per share, which are held by
the selling stockholder named in this prospectus. We issued the shares to the selling stockholder pursuant to a Stock Purchase Agreement, dated May&nbsp;13, 2024 (the &#147;Stock Purchase Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may resell or dispose of the shares of our common stock, or interests therein, at fixed prices, at prevailing market prices at the
time of sale or at prices negotiated with purchasers, to or through underwriters, broker-dealers, agents, or through any other means described in the section entitled &#147;Plan of Distribution&#148; beginning on page 11 of this prospectus. The
selling stockholder will bear all commissions and discounts, if any, attributable to the sale or disposition of the shares, or interests therein. We will bear all costs, expenses and fees in connection with the registration of the shares. We will
not receive any of the proceeds from the sale of these shares of our common stock by the selling stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq
Capital Market and trades under the symbol &#147;INKT.&#148; On August&nbsp;12, 2024, the last sale price of our common stock as reported on the Nasdaq Capital Market was $0.8350 per share. You are urged to obtain current market quotations for our
common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risks. See &#147;<A HREF="#tx792594_2">Risk Factors</A>&#148; beginning on page 5 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission, nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is &#8195;&#8195;&#8195;&#8195; , 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_4">DESCRIPTION OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_6">SELLING STOCKHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx792594_11">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus, including all documents incorporated herein by reference, together with additional
information described under &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may obtain the information incorporated by reference without charge by
following the instructions under &#147;Where You Can Find More Information&#148; before you make your investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have not authorized
anyone to provide you with information different from that contained or incorporated by reference in this prospectus. The selling stockholder may offer to sell, and seek offers to buy, shares of our common stock only in jurisdictions where offers
and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of selected information contained elsewhere or incorporated by reference in this prospectus. It does not contain all of the
information that you should consider before investing in our securities. You should read this entire prospectus carefully, especially the section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the notes to the
consolidated financial statements incorporated in this prospectus by reference. As used in this prospectus, &#147;MiNK,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Agenus Inc. and its consolidated
subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> invariant natural killer T
(&#147;iNKT&#148;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (&#147;NK&#148;) cells. iNKT
cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Our proprietary platform is designed to
facilitate scalable and reproducible manufacturing for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> delivery. As such, we believe that our approach represents a highly versatile application for
therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business activities include product research and development, manufacturing, regulatory and clinical development, corporate finance, and support of our
collaborations. To be successful, our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. We are a party to an Amended and Restated Intercompany Services Agreement and an
Intellectual Property Assignment and License Agreement with Agenus Inc. (&#147;Agenus&#148;). Under the Amended and Restated Intercompany Services Agreement, Agenus provides us with certain general and administrative support, including, without
limitation, financial, facilities management, human resources and information technology administrative support, and we and Agenus provide each other with certain research and development services and other support services, including legal and
regulatory support. We are also entitled to use Agenus&#146; business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such facilities and equipment, and we will be covered by certain
Agenus insurance policies, subject to certain conditions, including us paying the cost of such coverage. Under the Intellectual Property Assignment and License Agreement, Agenus exclusively assigned patent rights and
<FONT STYLE="white-space:nowrap">know-how</FONT> related to our technology to us. We also have a field-limited exclusive license under certain Agenus patents and <FONT STYLE="white-space:nowrap">know-how;</FONT> and we retain the rights to expand a
proprietary pipeline of products and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">agenT-797,</FONT> is an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> allogeneic, native iNKT cell therapy. iNKTs are a potent class of immune cells and serve as master regulators of immune response, possessing the killing power
of NK cells and the memory of <FONT STYLE="white-space:nowrap">T-cells.</FONT> Our proprietary manufacturing platform enables the infusion of these cells in billion-fold quantities, equipping the immune system to combat cancer and other
life-threatening diseases. We have successfully established and launched <FONT STYLE="white-space:nowrap">in-house</FONT> iNKT cell manufacturing and product release capacity, capable of supplying over 5,000 doses annually through a U.S. Food and
Drug Administration (&#147;FDA&#148;)-cleared scalable, fully closed, and automated process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development of
<FONT STYLE="white-space:nowrap">agenT-797</FONT> is advancing in multiple therapeutic areas of significant unmet needs. These include a Phase 2 trial in 2L gastric cancer and viral acute respiratory distress syndrome (&#147;ARDS&#148;) in
populations of patients where there are critical gaps in current treatment options. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In solid cancers, we completed a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">agenT-797</FONT>
in solid tumor cancers, both as a monotherapy and in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint inhibitors pembrolizumab and nivolumab. The trial demonstrated durable
clinical benefits with a tolerable safety profile across various heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> solid tumors, including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), testicular
cancer, and gastric cancer. Notably, the median progression-free survival exceeded six months, with approximately 30% of patients experiencing durable disease stabilization, even in cancers refractory to prior therapies such as pembrolizumab and
nivolumab. Building on these results, a randomized, Phase 2 investigator-sponsored trial led by Dr.&nbsp;Yelena Janjigian at Memorial Sloan Kettering Cancer Center is actively enrolling. This trial aims to evaluate the clinical safety and efficacy
of the combination of <FONT STYLE="white-space:nowrap">agenT-797,</FONT> botensilimab (a novel <FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> <FONT STYLE="white-space:nowrap">CTLA-4</FONT> inhibitor), balstilimab
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-1),</FONT></FONT> ramucirumab, and paclitaxel in patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. The study, which
is expected to enroll approximately 38 patients with advanced, unresectable, or metastatic forms of these cancers, is a priority program for us. Encouraging activity was observed with <FONT STYLE="white-space:nowrap">agenT-797</FONT> in both
monotherapy and combination settings, with durable responses and disease stabilization, as presented at the American Association for Cancer Research (&#147;AACR&#148;) and more recently at the Society for Immunotherapy of Cancer (&#147;SITC&#148;)
conference in November 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In inflammatory diseases, we have completed a phase 1 study<B> </B>of <FONT STYLE="white-space:nowrap">agenT-797</FONT> in
viral ARDS, leveraging the unique anti-inflammatory properties of iNKT cells. Results from our Phase 1 study were published in Nature Communications and presented at the American Thoracic Society International Conference over the past two years. We
reported an encouraging survival benefit of 75%, compared to approximately <FONT STYLE="white-space:nowrap">10-22%</FONT> in an <FONT STYLE="white-space:nowrap">in-hospital</FONT> control group and time-matched data from the Centers for Disease
Control and Prevention. In a cohort of 21 patients on mechanical ventilation, survival rates exceeded 70%, with an 80% survival rate among those on venovenous extracorporeal membrane oxygenation. In addition to a survival benefit, <FONT
STYLE="white-space:nowrap">agenT-797</FONT> improved lung function and significantly reduced inflammation and secondary infections, which are major contributors to comorbidity and mortality in intensive care units. Given the lack of approved
therapies for ARDS, we plan to advance <FONT STYLE="white-space:nowrap">agenT-797</FONT> in viral ARDS through strategic collaborations and <FONT STYLE="white-space:nowrap">non-dilutive</FONT> external financing into a randomized Phase 2 trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline is advancing next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are
<FONT STYLE="white-space:nowrap">(1)&nbsp;MiNK-215,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT> armored tumor stromal targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FAP-CAR-iNKT</FONT></FONT> and <FONT
STYLE="white-space:nowrap">(2)&nbsp;MiNK-413,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT> armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> program targeting BCMA program. <FONT STYLE="white-space:nowrap">MiNK-413</FONT> has
demonstrated tumor clearance and improved persistence in preclinical models, as well as manufacturing and logistical improvements over current BCMA cell therapies. <FONT STYLE="white-space:nowrap">MiNK-215</FONT> has demonstrated efficacy in NSCLC
and melanoma preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. These data and programs were presented at AACR in 2024, International
Cancer Immunotherapy Conference in 2023, SITC in 2023, and the American Society of Cell and Gene Therapy in 2023. Most recently, preclinical data from <FONT STYLE="white-space:nowrap">MiNK-215</FONT> in microsatellite stability colorectal cancer
liver metastases were presented at AACR 2024. This presentation highlighted <FONT STYLE="white-space:nowrap">MiNK-215&#146;s</FONT> potent anti-tumor activity, immune activation, and tumor stroma remodeling against this <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> solid tumor setting. Investigational new drug (&#147;IND&#148;) enabling activities are underway we expect to submit an IND to the FDA in 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, we announced a collaboration with ImmunoScape, Inc. (&#147;ImmunoScape&#148;) to discover and develop next-generation <FONT
STYLE="white-space:nowrap">T-cell</FONT> receptor therapies against novel targets in solid tumors. We will combine our unique, proprietary library of T cell antigens with ImmunoScape&#146;s platform for rapid discovery of novel T cell receptors.
ImmunoScape&#146;s unique Deep Immunomics platform enables high-throughput and sensitive screening of T cells against relevant tumor targets for the rapid discovery of rare, therapeutically-relevant <FONT STYLE="white-space:nowrap">T-cell</FONT>
receptors (&#147;TCRs&#148;). We have a proprietary library of phospho-peptide neoantigens derived from a wide range of solid tumors and hematologic malignancies. In this collaborative effort, ImmunoScape will leverage its capabilities in multiplex
antigen screening and <FONT STYLE="white-space:nowrap">in-depth</FONT> T cell profiling to identify relevant TCRs targeting the library of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
phospho-peptide antigens. We will further characterize these tumor-specific TCRs, leveraging its proprietary capabilities to analyze and select TCR candidates for optimal tumor targeting. Any
intellectual property resulting from the arrangement would be jointly owned by the parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in October 2017 and to MiNK
Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-994-8250.</FONT></FONT>
Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock offered by the selling stockholder </B></P></TD>
<TD>4,640,000 shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P></TD>
<TD>We will not receive any proceeds from the sale of shares in this offering. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P></TD>
<TD>An investment in our common stock involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 5 for a discussion of certain factors that you should consider before making an investment in our stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market Symbol </B></P></TD>
<TD>&#147;INKT&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before purchasing our securities, you should carefully consider the risk factors relating to MiNK
that are incorporated by reference in this prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as well as the risks, uncertainties and additional information set forth in
our SEC reports on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> and in the other documents incorporated by reference in this prospectus. For a
description of these reports and documents, and information about where you can find them, see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents By Reference.&#148; Additional risks not presently known or
that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein, and any prospectus supplement and the documents incorporated therein, contains
forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives
for future operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148;
and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy, short- and long-term business operations and objectives and financial needs. Examples of forward-looking statements include, among others, statements we make regarding: our business
strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new
accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place significant reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results and events to differ
materially from those indicated in the forward-looking statements include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, process and results of our research and development programs, preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may develop and successfully complete clinical trials and
obtain licensure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage our initial programs and to progress additional programs to create a clinical
portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, programs, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our collaborative relationship with Agenus Inc., as well as our ability to identify and
enter into future license agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, capital requirements and needs for additional financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as
predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we
undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_4"></A>DESCRIPTION OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation, or the Amended and Restated
Certificate of Incorporation, and amended and restated bylaws, or the Amended and Restated Bylaws are summaries and are qualified by reference to the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws, copies of
which are on file with the Commission as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023. Please refer to &#147;Where You Can Find More Information&#148; below for
directions on obtaining these documents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.00001 per share. As of June&nbsp;30, 2024, we had 39,445,520 shares
of common stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders
and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive
proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution
to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding
shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred
stock that we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Our Certificate of Incorporation and Our
<FONT STYLE="white-space:nowrap">By-laws</FONT></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation and Amended and Restated <FONT
STYLE="white-space:nowrap">By-Laws</FONT> contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or
preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions
include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified board. </I>The Amended and Restated Certificate of Incorporation provides that the board of directors is divided into three classes
of directors, with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of the board of directors is elected each year. The classification of directors will have the effect
of making it more difficult for stockholders to change the composition of the board. The Amended and Restated Certificate of Incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under
specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by
written consent; special meetings of stockholders.</I> The Amended and Restated Certificate of Incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in
lieu of a meeting. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted
by a majority of the board of directors. Except as described above, stockholders are not be permitted to call a special meeting or to require the board of directors to call a special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance notice procedures. </I>The Amended and Restated Bylaws establish an advance notice procedure for
stockholder proposals to be brought before an annual meeting of the stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations
specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who
has given the Secretary of the Company timely written notice, in proper form, of the stockholder&#146;s intention to bring that business before the meeting. Although the Amended and Restated Bylaws do not give the board of directors the power to
approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Amended and Restated Bylaws may have the effect of precluding the conduct of certain business at a
meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Supermajority approval requirements. </I>The Delaware General Corporation Law, or the DGCL, generally provides that the affirmative vote of a majority of
the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> unless either a corporation&#146;s certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws</FONT> requires a greater percentage. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the affirmative vote of holders of at least 75% of the total votes eligible
to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to the Amended and Restated Certificate of Incorporation and Amended and
Restated Bylaws could enable a minority of the Company&#146;s stockholders to exercise veto power over any such amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but unissued
shares. </I>The Company&#146;s authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes,
including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an
attempt to obtain control of a majority of the common stock by means of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive forum. </I>Our
Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in the name of the Company, actions against directors, officers and employees for breach of a fiduciary duty and
other similar actions may be brought only in specified courts in the State of Delaware. Under our Amended and Restated Certificate of Incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly does not apply to actions arising under
federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Furthermore, our Amended and Restated Certificate of Incorporation provides that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any compliant asserting a cause of action arising under the Securities Act.
Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against our directors
and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in
a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A
&#147;business combination&#148; includes, among other things, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested stockholder&#148; is a person who, together with affiliates
and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions: before the stockholder became interested, the corporation&#146;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of
the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by
the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by
the interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of
incorporation or an express provision in its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. The Company
has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of the Company may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is Equiniti Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering these shares pursuant to registration rights granted to the selling stockholder. We are not selling any securities under this prospectus
and will not receive any proceeds from the sale or other disposition of the shares covered hereby. We have agreed to pay all costs, expenses and fees relating to registering the shares of our common stock referenced in this prospectus. The selling
stockholder will pay any brokerage commissions and/or similar charges incurred in connection with the sale or other disposition by it of the shares covered hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_6"></A>SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared this prospectus to allow the selling stockholder or its pledgees, donees, transferees or other successors in interest, to sell or otherwise
dispose of, from time to time, up to 4,640,000 shares of our common stock (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2024, we entered into the Stock
Purchase Agreement with the selling stockholder, pursuant to which the selling stockholder purchased the Shares for an aggregate purchase price of $5.8&nbsp;million, or $1.25 per share. The selling stockholder owned approximately12% of the
outstanding shares of our common stock after such purchase. In accordance with the terms of the Stock Purchase Agreement, the selling stockholder has agreed (i)&nbsp;not to dispose of any of the Shares prior to November&nbsp;9, 2024 and (ii)&nbsp;to
vote the Shares in accordance with the recommendations of our board of directors in connection with all matters presented to our stockholders through May&nbsp;14, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with certain registration rights we granted to the selling stockholder pursuant to the Stock Purchase Agreement, we filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> of which this prospectus forms a part, with respect to the resale or other disposition of the shares of common stock offered by this prospectus from time to time on the
Nasdaq Capital Market, in privately negotiated transactions or otherwise. We have agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period
of time required under the Stock Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of the Shares in connection with the Stock Purchase Agreement was not registered under
the Securities Act, in reliance upon exemptions from registration provided by Section&nbsp;4(a)(2) of the Securities Act, because the transactions did not involve any public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the selling stockholder and the shares of common stock that the selling stockholder may offer and sell from
time to time under this prospectus. Neither the selling stockholder nor any of its affiliates, officers, directors or principal equity holders have held any position or office or had any other material relationship with us or our affiliates within
the past three years, other than a Manager of the selling stockholder acting as an observer on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This table is prepared based on
information supplied to us by the selling stockholder, and reflects holdings as of August&nbsp;13, 2024. As used in this prospectus, the term &#147;selling stockholder&#148; includes the selling stockholder set forth below and any donees, pledgees,
transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares received after the date of this prospectus from the selling stockholder as a gift, pledge, or other <FONT
STYLE="white-space:nowrap">non-sale</FONT> related transfer. Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated by the SEC under the Exchange Act, and includes shares of common
stock with respect to which the selling stockholder has voting and investment power. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares in the column &#147;Maximum Number of Shares of
Common Stock that may be Offered Pursuant to this Prospectus&#148; represents all of the shares of our common stock that the selling stockholder may offer under this prospectus. The fourth column assumes the sale of all the shares offered by the
selling stockholder pursuant to this prospectus and that the selling stockholder does not acquire any additional shares of common stock before the completion of this offering. However, because the selling stockholder may sell all or some of its
shares under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholder or that will be held by the selling stockholder after completion of
any sales. The selling stockholder may sell some, all or none of their shares in this offering. We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or
understandings with the selling stockholder regarding the sale of any of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;of</B><br><B>Common&nbsp;Stock&nbsp;Prior&nbsp;to&nbsp;the</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares of<BR>Common<BR>Stock<BR>that May<BR>Be<BR>Offered<BR>Pursuant&nbsp;to<BR>This<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;of<BR></B><br><B>Common&nbsp;Stock&nbsp;After&nbsp;the<BR></B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent of<BR>Class<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of<BR>Class<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GKCC, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that all the shares of the selling stockholder covered by this prospectus are sold, and that the
selling stockholder does not acquire any additional shares of common stock before the completion of this offering. However, because the selling stockholder can offer all, some, or none of its common stock, no definitive estimate can be given as to
the number of shares that the selling stockholder will ultimately offer or sell under this prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder, including its pledgees, donees, transferees, distributees, beneficiaries or other successors in interest, may from time to time offer
some or all of the shares of common stock covered by this prospectus. We will not receive any of the proceeds from the sale of the shares of common stock covered by this prospectus by the selling stockholder. We will bear all fees and expenses
incident to our obligation to register the shares of our common stock covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may sell all or a portion of
the shares of common stock beneficially owned by it and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the
selling stockholder will be responsible for underwriting discounts or commissions or agent&#146;s commissions. The shares of common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or
quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at privately negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may use any one or more of
the following methods when disposing of shares or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the effective date of the registration statement of which this prospectus is a part;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholder to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by it and, if it
defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of the selling stockholder to include the pledgee, transferee, or other successors in interest as selling stockholder under this prospectus. The selling stockholder also may transfer the
shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of shares of our common stock or interests therein, the selling stockholder may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions it assumes. The selling stockholder may also sell shares of our common stock short and deliver these
securities to close out its short positions, or loan or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial
institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholder may
arrange for other broker-dealers to participate in sales. If the selling stockholder effects certain transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may
receive commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom they may sell as principal. Such commissions
will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with applicable rules of the Financial
Industry Regulatory Authority (&#147;FINRA&#148;); and in the case of a principal transaction a markup or markdown in compliance with applicable FINRA rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholder from the sale of the common stock offered by it will be the purchase price of the common stock less
discounts or commissions, if any. The selling stockholder reserves the right to accept and, together with its agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We
will not receive any of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder also may resell all or a portion of the shares in open market
transactions in reliance upon Rule 144 under the Securities Act, provided that it meets the criteria and conforms to the requirements of that rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
selling stockholder and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act. Any
discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. The selling stockholder is subject to the prospectus delivery requirements of the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required pursuant to Rule 424(b) under the Securities Act, the shares of our common stock to be sold, the name of the selling
stockholder, the purchase price and public offering price, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or,
if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of
some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale
or an exemption from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder and any other person
participating in a sale of the common stock registered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation
M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock by the selling stockholder and any other participating person. All of the foregoing may affect the marketability of the shares of common
stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to
the selling stockholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholder may indemnify any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the securities that may be offered hereby will be passed upon for us by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_9"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of MiNK Therapeutics, Inc. as of December&nbsp;31, 2023 and 2022 and for the years then ended, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public
accounting firm, incorporated by reference herein and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December&nbsp;31, 2023 consolidated financial statements contains an explanatory paragraph
that states that the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about the entity&#146;s ability to continue as a going concern. The consolidated financial statements do not
include any adjustments that might result from the outcome of that uncertainty. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_10"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the Commission. The Commission maintains an
Internet site at http://www.sec.gov that contains the reports, statements and other information about issuers, such as us, who file electronically with the Commission. We also maintain a website at www.minktherapeutics.com, at which you may access
these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the Commission. Information contained on or accessible through our website is not a part of this prospectus or any prospectus
supplement, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx792594_11"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; in this prospectus the information we file with the SEC. This helps us disclose certain important
information to you by referring you to the documents we file. The information we incorporate by reference is an important part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually
updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the
statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. We incorporate by reference each of the documents listed below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017024034672/inkt-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017024059081/inkt-20240331.htm">March
<U></U>&nbsp;31, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024096142/inkt-20240630.htm">June&nbsp;30, 2024</A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017024014944/inkt-20240212.htm">February
<U></U>&nbsp;14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017024060805/inkt-20240513.htm">May<U></U>&nbsp;
16, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017024074233/inkt-20240612.htm">June<U></U>&nbsp;17, 2024</A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024050064/2024_proxy.htm">Schedule
 14A</A> filed with the SEC on April&nbsp;29, 2024 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521297781/d232393d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed with the Commission on October&nbsp;13, 2021, including any amendment or report filed for the purpose of updating such
description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the
registration statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this
prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
provide each person, including any beneficial owner, to whom this prospectus is delivered a copy of all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus. You may obtain copies of
these filings, at no cost, through the &#147;Investor&nbsp;&amp; Media&#148; section of our website (www.minktherapeutics.com), and you may request copies of these filings, at no cost, by writing or telephoning us at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MiNK Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 Fifth
Avenue, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10010 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (212) <FONT STYLE="white-space:nowrap">994-8250</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained on our website is not a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;, 2024 </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g792594g79d59.jpg" ALT="LOGO" STYLE="width:2.86126in;height:0.914129in;">
 </P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>4,640,000 Shares of Common Stock </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Other Expenses of Issuance and Distribution</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the various expenses in connection with the registration of the securities offered hereby. MiNK Therapeutics, Inc. will bear all
of these expenses. All amounts are estimated except for the SEC registration fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,046.52</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) These
amounts are estimates. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Indemnification of Directors and Officers</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by Section&nbsp;102(b)(7) of the DGCL, our Amended and Restated Certificate of Incorporation includes a provision to eliminate the personal
liability of our directors for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provides that we are
required to indemnify our officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and we are required to advance expenses to our officers and directors as incurred
in connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a
director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably
believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by
judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not
opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or
was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#146; fees) actually and reasonably incurred
by him in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that,
despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and certain of our officers. These indemnification agreements provide broader indemnity
rights than those provided under the DGCL and our Amended and Restated Certificate of Incorporation. These indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against us or our directors or
officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by us, and we would not benefit from derivative recoveries
against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain directors&#146; and officers&#146; liability insurance for the benefit of our directors and officers. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Exhibits</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Exhibits are incorporated herein by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex31.htm">Amended and Restated Certificate of Incorporation of MiNK Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed on October&nbsp;20, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex32.htm">Amended and Restated Bylaws of MiNK Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#146;s Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed on October&nbsp;20, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex41.htm">Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Company&#146;s Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259503),</FONT> as amended, filed on October&nbsp;12, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024096142/inkt-ex10_1.htm">Stock Purchase Agreement, dated May&nbsp;
14, 2024, by and between MiNK Therapeutics, Inc. and GKCC, LLC (incorporated by reference to Exhibit 10.1 to the Company&#146;s Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-40908)</FONT> filed on August&nbsp;13, 2024). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d792594dex51.htm">Opinion of Ropes&nbsp;&amp; Gray LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d792594dex51.htm">Consent of Ropes&nbsp;&amp; Gray LLP (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d792594dex232.htm">Consent of KPMG LLP, an independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d792594ds3.htm#sig">Power of Attorney (included in the signature page to this Registration Statement). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d792594dexfilingfees.htm">Filing Fee Table* </A></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Undertakings</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) to file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus
required by Section&nbsp;10(a)(3) of the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value
of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in
the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that the undertakings set forth in paragraphs (a)(1)(i), (a)(I)(ii) and
(a)(I)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or
Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i). Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii). Each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities
Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however , that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
effective date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing prospectus relating to the offering
containing material information about the undersigned registrant or its securities provided by or on behalf of an undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iv) Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) That, for purposes of determining any
liability under the Securities Act, each filing of registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant
to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(7) That, for purposes of determining liability under the Securities Act: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) the information omitted from the form of prospectus filed as part of this registration statement in reliance upon 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) each post-effective amendment that contains a form of prospectus shall be deemed a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(9) If and when applicable, the undersigned registrant hereby undertakes to
file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under
Section&nbsp;305(b)(2) of the Trust Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on this 13<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day of August, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MINK THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jennifer S. Buell, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8201;Jennifer S. Buell, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8201;<I>President, Chief Executive Officer and Director</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jennifer S. Buell and Christine M. Klaskin, as his
or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, with full power of substitution and revocation, for him or her and in his or her name, place and stead, in any and all
capacities, to execute any or all amendments including any post-effective amendments and supplements to this Registration Statement, and any additional Registration Statement filed pursuant to Rule 462(b), and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority
to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities
and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>SIGNATURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>TITLE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>DATE</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer S. Buell, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jennifer S. Buell, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christine M. Klaskin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christine M. Klaskin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasurer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Garo H. Armen, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Garo H. Armen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Behner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Peter Behner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Corvese</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Brian Corvese</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barbara Ryan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Barbara Ryan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ulf Wiinberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ulf Wiinberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;13, 2024</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d792594dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g792594g0813122941683.jpg" ALT="LOGO" STYLE="width:2.05069in;height:0.986111in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">August&nbsp;13, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiNK Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">49 Fifth Avenue, Suite 500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10010 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to MiNK Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with the
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<U>Registration Statement</U>&#148;) filed on the date hereof by the Company with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under
the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), relating to the registration under the Securities Act and the proposed offer and sale from time to time by the selling stockholder named in the Registration Statement
pursuant to Rule 415 under the Securities Act of 4,640,000 shares of the common stock, $0.00001 par value per share, of the Company (the &#147;<U>Securities</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion letter, we have examined such certificates, documents and records and have made such investigation of fact and
such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company,
public officials and other appropriate persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed below are limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Securities have been duly authorized and are validly issued, fully
paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to your filing this opinion as an exhibit to the
Registration Statement and to the use of our name therein and in the related prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required
under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ropes&nbsp;&amp; Gray LLP </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d792594dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g792594g21u88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:ARIAL">KPMG LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:ARIAL">Two
Financial Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:ARIAL">60 South Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:ARIAL">Boston, MA
02111 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated March&nbsp;21,&nbsp;2024, with respect to the consolidated financial statements of MiNK Therapeutics, Inc,
incorporated herein by reference, and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;13,&nbsp;2024 </P> <P STYLE="margin-top:120pt; margin-bottom:0pt; margin-left:24%; font-size:6.5pt; font-family:ARIAL">KPMG LLP,
a Delaware limited liability partnership and a member firm of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:6.5pt; font-family:ARIAL">the KPMG global organization of independent member firms affiliated with </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:6.5pt; font-family:ARIAL">KPMG International Limited, a private English company limited by guarantee. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d792594dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Table 1: Newly Registered Securities </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Security&nbsp;Type&#8194;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Calculation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(1)</B></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price Per</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Unit</B></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common&nbsp;stock,&nbsp;$0.00001</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rules&nbsp;457(c)&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">4,640,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.798 (2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$3,702,720.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.00014760</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$546.52</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$3,702,720.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$546.52</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Total Fee Offsets (3)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$546.52</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant is hereby registering for resale from time to time by certain stockholders up to 4,640,000
shares of its common stock that were initially issued pursuant to the Stock Purchase Agreement dated as of May&nbsp;14, 2024, by and between the Registrant and GKCC, LLC. Pursuant to Rule&nbsp;416&nbsp;under the&nbsp;Securities Act, this
Registration Statement also covers such additional securities that may be issued as a result of stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) based on
the average of the high and low prices of the registrant&#146;s Common Stock as reported on the Nasdaq Capital Market on August&nbsp;9, 2024 to be $0.8110 and $0.7850, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant does not have any fee <FONT STYLE="white-space:nowrap">off-sets.</FONT></P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g792594g0813122941683.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g792594g0813122941683.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != ,(# 2(  A$! Q$!_\0
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M..#^Q(FU'[;]CDA6XEDB4^4)0RO' S%<,O)1<<YP!D@$M[X4OY_%?]MVVLK
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MV> ,T =G17-6/BF2Z\87>@/;6H:V4;VAO/,E4^7&^7CV#:A\S:&R<E>@KI:
M"BBB@ HHHH *\I\-_P#) +W_ *];K^;5ZM7%Z5X0NK#X;3^%Y+JW:[DAFC$B
MYV N20?7O5Q:2^XSFFW\F9VN_P#)"#_V"X?Y+1XX_P"1!T'_ *^[+^E='+X9
M%YX#7PW=38/V-;=I8QP&"@9&?<9K!;PKXDU6'2]+UK4-,_LZPECE9K9'\Z?R
M_N@@\+[XIIJY,D_P+'C_ /Y"7A#_ +#,7\C7<5SOB70)];N]#FAFBC73[]+J
M0/GYE Z#'>NA^E2WHBXIILX?P_\ \E6\6?\ 7"U_]!K4\5ZO>:5=^'X[2146
M\U..WF!4'<A!R.>G3K6?-X?\1V?C#5-:TBXTKR[](D*78D)78,?PU<US0-4U
MS1M.+W5I!K5C<I=1NB,82ZYXP><$&JTNF0K\K2,_6?\ DK_AHCJ;*Y!_*NYK
MCM/\/ZW=^+;;7]>N+!7LX'AM[>R#8^;JS%OY5V-3+HBX7U9#=6L-Y;26UPF^
M*089<D9'X5!>:597\JR7,&]U "MN(*X8.",'@AE4YZ\5'KM[/IVAWEW;",SQ
M1DQB0$@MT P"">>@R,GC(ZURL/B_5F,&\6)\AX4O(Q"ZR2F6Y> !!O/ELNS<
M5._). <?,9+.@_X1+10UXPMI1]L1TE N9<*';<^P;L1Y8 G9MR0#UI&\(Z0U
MI';!+Q DQG\V._G29G*[2S2JX=CMP.6/ 'H*RK'Q/J<GA_5;ZX-A+-;Z:FHP
M&V5O+ ='98VRQ+$;.2,9# X%16'B'Q!?+'ITAL+#5A+.)GNK8E%6-8V"^6DQ
M&XK*IXD8  GKP #IDT/38[RWNTM5%Q;M,T4FXY4RMND[]R<X[=L5%/X;TBZL
MK>RN+));:W@%O'$[,5\L,C;2"?F&8DSG.<8/!.>=?Q;K!TW[5'9VH5M+;4UD
M.63:L1R@Y!)\S80W *-ZC-;.J7VJP:];6L$EM;65Q$4BFEM6FWW!#D*2LB[
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M[=Y[^,B2/&Y"5ZC/I3;&TDT;XC6]O=W,FI27EFYAN;@_O(0IY48^7!^@-/\
M$O3P9_U_P_\ H%6=3_Y*EH7_ %Y3T"*L,(U"]\=,1G>HME_X#">/S-2VR'5_
MA'&G\1TWC_>0<?JM4_#N@C6TUB_.IZE;"XU&<!+:?8C ':"1CFK/@UR?AK-
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JD]Q6WVHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g792594g21u88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g792594g21u88.jpg
M_]C_X  02D9)1@ ! 0$ ;@!N  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MW\8,,&_T+0.A_P"F-U17Y3BOC7I'_P!)1]=0^'YO\V?BO_P7(UR^_P""@?\
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MY;:+LGJ]>MNVO'1X;C3Q%;$MIN=^732-S\0?^#6O]CGPA\=M9^,'BSQUX/\
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0=RE*;YI.[\SZ:,4E9(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g792594g79d59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g792594g79d59.jpg
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M 0$  P # 0               P0% 0(&!__$ #H1  (" @ $ P4&! 8" P
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M%73S20-J Z ,U<BYPRVN&WM2K!66^%!W0:/]&Q^TE0$]_P#$+AW\E7;]F/\
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M-[)8VR1.:]CP'-<TY@@[B"OI5?P<[U-=M'K(*EY?);YW4K7':2S(.;Y@[+J
M5H( B(@"(B (B( B*E]-^E06..:PX=F!NKAJU%0P_%A^*/S_ $=>X#XTS:77
MV*H-FPK-&ZY,=^$U.J'MA_, .8+N?FW;]U5_=GQU^66?ND/^A5ZYQ<XN<27$
MYDG>5^("P_NSXZ_++/W2'_0GW9\=?EEG[I#_ *%7BN#0IHK?B.6.]8@B<RS,
M.<4+MAJB/X.GEW<Z L30S7X[Q*&WC$=U,=F_J812Q-=4GGS#<PT<_+R*WE\Q
M1LAB9'$QK(V -:UHR#0-P 7T@"(B _'.:QI<\AK0,R2<@ J6TC:1I*UTMLP_
M*8Z0=K+4MV.EYPT\C>GEZM_WI:QLZJEEL=IERIV'5J96G^D/X@Z!R\Y^NK%0
MR,C_ &0/6<'X0DED7KKX+]V$1%1/3A$1 $1$ 1$0!$1 $1$!.-'^/:K#LK*2
MM+ZBU$Y%F>;H>EO1T*^Z"LIZ^CBJJ.5LU/*W68]IV$+)BFVC3&<F'*\4M8]S
MK5.[MQOXIWXX^T*YCY'+[LNQY_BW"%>G=2O>\5Y_U^IH1%\QO;)&U\;@YC@'
M-<TY@@\H7TM$\8$1$ 1$0!$1 $1$ 1$0!$1 $1$!0O"N^)8;\)/Z&+.ZT1PK
MOB6&_"3^ABSN@"(B +8^A+$/OAT>VZ21^M54@[$FV[<V9 'RMU3Y5CA71P8<
M0]A8FK;),_**X1<9$#_:LVY#K:7?LA ::1$0!$1 $1$ 1$0!$1 ?,LC(8GR2
MN#8V-+G..X ;RL.X[OS\38NNEV>3J5$QXH'Z,8V,'[("T[I]Q%[@Z/JN&)^K
M57$]B1Y';JGX9_9!'ZP61$ 1$0!2_1#W2\.^-M^U1!2_1#W2\.^-M^U ;31$
M0!>?B"U0WNQU]LJOZ&KA="XC>,QEF.D;_(O01 84Q7AVX87O51;+K"Z.:(]J
M[+M9&\CVGE!7DM:7.#6@EQ.0 Y5O"^6*UWZF%/>;?35L0VM$S [5/.#O'D7E
MV/ F&+'5"IM=DHX*@;6RZNNYO479D>1 1'@_8*J,+X<J*VZ1&*XW(M>8G#)T
M4;<]4'F)S)(Z1S*TT1 $1$ 66^%!W0:/]&Q^TE6I%EOA0=T&C_1L?M)4!4*(
MB +UL)W^KPSB"CNUO=E-3OS+<]CV[G-/01F%Y*(#>&&KU28AL='=;<_7IJF,
M/;SM/*T](.8/4O267^#MCGW%O1P_<9<K?<'CB7..R*?</([8.O+I6H$ 1$0!
M$1 $1$ 4$TZ=RJ_]Y%[9BG:@FG3N57_O(O;,0&.$1$!9'!X[J=M\%-[-RUTL
MB\'CNIVWP4WLW+72 (B( L\\*_XSAKO*CTQK0RSSPK_C.&N\J/3&@*#1$0&E
M^"O\U+QXZ/4:KK5*<%?YJ7CQT>HU76@"(B (B( B*I--6E*/#%/)9['(V2]R
M-R?(-HI6GE/Y_,.3>>3,#ATV:4VX=AELE@E:Z\O;E-,W:*5I'KGZM_,LP2/?
M)(Z21SGO<2YSG',DGE)7[-+)/,^69[I)7N+G/<<RXG>2>4KX0!$5M:%M%LF*
M*B.[WR-T=CC=FQAV&J<.0?F<YY=PY2 /O0KHL?B::.\WV-S+)&[..([#5.'\
M'.>7<.7+4<4;(8F10L;'&P!K6-&0:!N ',OR"&.GACA@C;'%&T-8Q@R#0-P
MY OM $1$ 4'TK8J-@LW8M')E<:P%K"#MC9RNZ^0?_BFL\K((9)97!D<;2YSC
MN &TE9AQA>Y,08@JJ^0GBW.U8FGZ,8^"/MZR57R;>2.EW9L\%P5E7<TU[L?K
MX(\9$191[H(B( B(@"(B (B( B(@"(B (B("Y-"V*3/";#729R1 OI7..]O*
MSR;QT9\RM99.ME;-;;A3UE*[4G@>'L/2/L6H[%<X;Q:*2X4_]'/&'Y?BGE'D
M.86EBV\T>5^!XOCV$J;?;0727U_K_,[R(BMF $1$ 1$0!$1 $1$ 1$0!$1 4
M+PKOB6&_"3^ABSNM$<*[XEAOPD_H8L[H B+V[A8WT^%+3>V F&JEFIW_ )KV
M$$>=KO\ *4!XB]'#EUFL=]H+I3?TM),V4#/X61VCJ(V>5><B WW;ZR&X4%-6
M4K]>GJ(VRQNYVN&8/F*YU5/!PQ#[K8%]SY7ZU3:Y##D=_%N[9A]8?JJUD 1$
M0!$1 $1$ 1%YN);O#8;!<+I4Y<520NE(S^$0-C?*<AY4!F?A(8B]UL;MML+]
M:FM<?%;#LXUVUY]4?JE5.N>X5<U?7U-95/+ZBHD=+(X\KG$DGSE<" (O<P98
MGXAO78HS$,4,E3,X?1CC:7'SY >5>&@"E^B'NEX=\;;]JB"E^B'NEX=\;;]J
M VFB(@"(B (B( B(@"(B ++?"@[H-'^C8_:2K4BRWPH.Z#1_HV/VDJ J%$1
M$4GK\)SQ8$M>)J?6?2SRR4]0/[-X<=4]1&SK'2%&$!^M):X.:2' Y@CD6O\
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MY$ 1$0!$1 033)>#;<*.I8G935S^*V;]0;7?8/UE0"L/3?<34XIBHVGM*2
MC\YW;'ZM55XLK)GS6/Y'ON"X_L<2+\9=?Y?H$1%7-4(B( B(@"(B (B( B(@
M"(B (B( KCT$W@R4U=9Y79F(]D1 _BG8X>?(^4JG%)=&UR-KQG;92[*.63B'
M]3^U^HD'R*:B?)-,H<3Q_P"(Q9P\>Z]4:51$6N?.PB(@"(B (B( B(@"(B (
MB("A>%=\2PWX2?T,6=UHCA7?$L-^$G]#%G= %?&#L/>^7@[7*FC;KU5-52U4
M'/KL .0ZVZP\JH=:JX,QUM'$@RW5TH_RL0&544LTJ8>][..KK;V,U:8R<=3[
M-G%O[8 =6>7D430%F\'G$/N+C^&EE?JTUS8:9V>[7WL/7F,OUEK58!I9Y:6I
MAJ*=Y9-$\2,<-[7 Y@^=;HPE>8L0X:MMVARU:J!LA ^B[+MF^0YCR(#UD1$
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MHR ;\N8[QUY<B ER(B (B( H)IT[E5_[R+VS%.U!-.G<JO\ WD7MF(#'"(B
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MK"AHZ>@HX:2BA9!30M#(XV#)K0.0!?EOHJ:W44%'0PL@I86AD<;!D&@<B["
M(B( B(@"(B (B(#(I&1R*+M76$T]SK(#OCF>SS.(756&?4HOF6T$1%P<A$1
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MW>DOUFI+I;I.,I:F,2,/*.<'I!S!Z0@/04&TX]RN_P#@X_:L4Y4&TX]RN_\
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M%DGOS0.ACYCP^'D]*G*@VACYCP^'D]*G*V:?AH^<\1^]6>K"(BD*01$0!$1
M$1$ 1$0!$1 4+PKOB6&_"3^ABSNM$<*[XEAOPD_H8L[H M&\%(_^48A;S3Q'
M_*Y9R6B>"B?_ "_$8SW2P>AZ OE$1 %1_"AP[V39;??H&9R4;^QYR!_5O^"3
MU.V?KJ\%Y6*K-%B##EQM51EJ5<+HP3]%V7:N\AR/D0&$D7-64TM'63TM2PLG
M@>Z.1I^BX'(CSA<* U!P9<0^Z&$:FSS/SGMLN; 3_5/S(\SM;ZE(-.^(O>_H
M^K6Q/U:JO_ XLM^3@=<_LAWE(6==#^+X\&XPBK:PR>Y\T;H*D,&9#3M#LN7(
M@'JS7JZ<\=TN,[Y2,M#Y'6NBC(8Y[2W7>X]L[([<L@T;>8H"M$1=RS6Z>[W:
MCMU(W6J*J5L+!TN.7F0&C.#%AOL+#M9?9V935[^*A)&Z)AVD=;L_V0KJ71L5
ML@LMFHK;2#*"EA;"SI &69Z3O\J[R (B(",Z3CJZ.\2G_P!OF'^0K$:VUI1.
M6CK$F?\ P$OJE8E0!2_1#W2\.^-M^U1!2_1#W2\.^-M^U ;31$0!033GW*K_
M -Y'[5BG:@FG/N57_O(_:L0&.$1$!=W!6^<UZ\3;ZX6E%FO@K?.:]>)M]<+2
MB (B( LM\*#N@T?Z-C]I*M2++?"@[H-'^C8_:2H"H41$!J[@U=S5OCDO\*M1
M57P:NYJWQR7^%6H@"(B (B( LHZ?L#^]K$?NI01:MJN+B\!HV12[W,Z =X\H
MY%JY>)C/#E)BK#E9::X ,G;VDF69C>/@N'4?JS'*@,,(N]?;55V.\5=LN$?%
MU5-(8WCDV<HZ"-H/,5T4!*]&6+IL&8JIKBS6=2.^]540^G$3M\HWCI"TYI<J
M8*[1)>JJED;-3S4K)(WMVAS2YI!"QPK2PAC;C=%N),*7*7MF4QEH7..\:P+H
M_)\(?K<P0%6HB("R.#QW4[;X*;V;EKI9%X/'=3MO@IO9N6ND 1$0!9YX5_QG
M#7>5'IC6AEGGA7_&<-=Y4>F- 4&B(@--<%CYGW;Q_P#Z;%="I?@L?,^[>/\
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MQ-8]SK+6.#:AN_BG;A(!T<O..H(#7R+XAECGA9+"]LD3VAS7M.8<#N(/,OM
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M0R_G\Q[HWM>QQ:]IS#@<B#SK6NA'2$W%]F["N,@]VZ-H$N?]>S<)!T\AZ>M
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M*Z7W.<'_ -W+;_@A 9PX/'=3MO@IO9N6NEX%HP9ARSUS*RUV:BI:I@(;+%&
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M?Y)H? ,]4*I"N#MDM+P/09.;D1P*)JQ[;EM[>WU.Q!$R"&.*(91QM#6C//(
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M[J(I$M+2*<I.<G*7=A4WB'NZ6[OH?55R*F\0]W2W=]#ZJ@R>T?5&OP7XEO\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
